Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2) : a multicentre, parallel-group, superiority, randomised controlled trial
Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Placental growth factor (PlGF)-based testing has high diagnostic accuracy for predicting pre-eclampsia needing delivery, significantly reducing time to diagnosis and severe maternal adverse outcomes. The clinical benefit of repeat PlGF-based testing is unclear. We aimed to determine whether repeat PlGF-based testing (using a clinical management algorithm and nationally recommended thresholds) reduces adverse perinatal outcomes in pregnant individuals with suspected preterm pre-eclampsia.
METHODS: In this multicentre, parallel-group, superiority, randomised controlled trial, done in 22 maternity units across England, Scotland, and Wales, we recruited women aged 18 years or older with suspected pre-eclampsia between 22 weeks and 0 days of gestation and 35 weeks and 6 days of gestation. Women were randomly assigned (1:1) to revealed repeat PlGF-based testing or concealed repeat testing with usual care. The intervention was not masked to women or partners, or clinicians or data collectors, due to the nature of the trial. The trial statistician was masked to intervention allocation. The primary outcome was a perinatal composite of stillbirth, early neonatal death, or neonatal unit admission. The primary analysis was by the intention-to-treat principle, with a per-protocol analysis restricted to women managed according to their allocation group. The trial was prospectively registered with the ISRCTN registry, ISRCTN 85912420.
FINDINGS: Between Dec 17, 2019, and Sept 30, 2022, 1253 pregnant women were recruited and randomly assigned treatment; one patient was excluded due to randomisation error. 625 women were allocated to revealed repeat PlGF-based testing and 627 women were allocated to usual care with concealed repeat PlGF-based testing (mean age 32·3 [SD 5·7] years; 879 [70%] white). One woman in the concealed repeat PlGF-based testing group was lost to follow-up. There was no significant difference in the primary perinatal composite outcome between the revealed repeat PlGF-based testing group (195 [31·2%]) of 625 women) compared with the concealed repeat PlGF-based testing group (174 [27·8%] of 626 women; relative risk 1·21 [95% CI 0·95-1·33]; p=0·18). The results from the per-protocol analysis were similar. There were four serious adverse events in the revealed repeat PlGF-based testing group and six in the concealed repeat PlGF-based testing group; all serious adverse events were deemed unrelated to the intervention by the site principal investigators and chief investigator.
INTERPRETATION: Repeat PlGF-based testing in pregnant women with suspected pre-eclampsia was not associated with improved perinatal outcomes. In a high-income setting with a low prevalence of adverse outcomes, universal, routine repeat PlGF-based testing of all individuals with suspected pre-eclampsia is not recommended.
FUNDING: Tommy's Charity, Jon Moulton Charitable Trust, and National Institute for Health and Care Research Guy's and St Thomas' Biomedical Research Centre.
| Errataetall: |
ErratumIn: Lancet. 2024 Mar 23;403(10432):1140. - PMID 38521557 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:403 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 403(2024), 10427 vom: 17. Feb., Seite 619-631 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hurrell, Alice [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
144589-93-5 |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 23.03.2024 published: Print-Electronic ErratumIn: Lancet. 2024 Mar 23;403(10432):1140. - PMID 38521557 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0140-6736(23)02357-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36831698X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36831698X | ||
| 003 | DE-627 | ||
| 005 | 20240324235025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240212s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(23)02357-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1344.xml |
| 035 | |a (DE-627)NLM36831698X | ||
| 035 | |a (NLM)38342128 | ||
| 035 | |a (PII)S0140-6736(23)02357-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hurrell, Alice |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2) |b a multicentre, parallel-group, superiority, randomised controlled trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Lancet. 2024 Mar 23;403(10432):1140. - PMID 38521557 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Placental growth factor (PlGF)-based testing has high diagnostic accuracy for predicting pre-eclampsia needing delivery, significantly reducing time to diagnosis and severe maternal adverse outcomes. The clinical benefit of repeat PlGF-based testing is unclear. We aimed to determine whether repeat PlGF-based testing (using a clinical management algorithm and nationally recommended thresholds) reduces adverse perinatal outcomes in pregnant individuals with suspected preterm pre-eclampsia | ||
| 520 | |a METHODS: In this multicentre, parallel-group, superiority, randomised controlled trial, done in 22 maternity units across England, Scotland, and Wales, we recruited women aged 18 years or older with suspected pre-eclampsia between 22 weeks and 0 days of gestation and 35 weeks and 6 days of gestation. Women were randomly assigned (1:1) to revealed repeat PlGF-based testing or concealed repeat testing with usual care. The intervention was not masked to women or partners, or clinicians or data collectors, due to the nature of the trial. The trial statistician was masked to intervention allocation. The primary outcome was a perinatal composite of stillbirth, early neonatal death, or neonatal unit admission. The primary analysis was by the intention-to-treat principle, with a per-protocol analysis restricted to women managed according to their allocation group. The trial was prospectively registered with the ISRCTN registry, ISRCTN 85912420 | ||
| 520 | |a FINDINGS: Between Dec 17, 2019, and Sept 30, 2022, 1253 pregnant women were recruited and randomly assigned treatment; one patient was excluded due to randomisation error. 625 women were allocated to revealed repeat PlGF-based testing and 627 women were allocated to usual care with concealed repeat PlGF-based testing (mean age 32·3 [SD 5·7] years; 879 [70%] white). One woman in the concealed repeat PlGF-based testing group was lost to follow-up. There was no significant difference in the primary perinatal composite outcome between the revealed repeat PlGF-based testing group (195 [31·2%]) of 625 women) compared with the concealed repeat PlGF-based testing group (174 [27·8%] of 626 women; relative risk 1·21 [95% CI 0·95-1·33]; p=0·18). The results from the per-protocol analysis were similar. There were four serious adverse events in the revealed repeat PlGF-based testing group and six in the concealed repeat PlGF-based testing group; all serious adverse events were deemed unrelated to the intervention by the site principal investigators and chief investigator | ||
| 520 | |a INTERPRETATION: Repeat PlGF-based testing in pregnant women with suspected pre-eclampsia was not associated with improved perinatal outcomes. In a high-income setting with a low prevalence of adverse outcomes, universal, routine repeat PlGF-based testing of all individuals with suspected pre-eclampsia is not recommended | ||
| 520 | |a FUNDING: Tommy's Charity, Jon Moulton Charitable Trust, and National Institute for Health and Care Research Guy's and St Thomas' Biomedical Research Centre | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Placenta Growth Factor |2 NLM | |
| 650 | 7 | |a 144589-93-5 |2 NLM | |
| 700 | 1 | |a Webster, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Sparkes, Jenie |e verfasserin |4 aut | |
| 700 | 1 | |a Battersby, Cheryl |e verfasserin |4 aut | |
| 700 | 1 | |a Brockbank, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Duhig, Kate E |e verfasserin |4 aut | |
| 700 | 1 | |a Gill, Carolyn |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Hunter, Rachael M |e verfasserin |4 aut | |
| 700 | 1 | |a Seed, Paul T |e verfasserin |4 aut | |
| 700 | 1 | |a Vowles, Zoe |e verfasserin |4 aut | |
| 700 | 1 | |a Myers, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Shennan, Andrew H |e verfasserin |4 aut | |
| 700 | 1 | |a Chappell, Lucy C |e verfasserin |4 aut | |
| 700 | 0 | |a PARROT-2 trial group |e verfasserin |4 aut | |
| 700 | 1 | |a Ahuja, Ashwin |e investigator |4 oth | |
| 700 | 1 | |a Alexander, Hazel |e investigator |4 oth | |
| 700 | 1 | |a Arya, Rita |e investigator |4 oth | |
| 700 | 1 | |a Bahl, Rachna |e investigator |4 oth | |
| 700 | 1 | |a Bapir, Mihraban |e investigator |4 oth | |
| 700 | 1 | |a Barry, Natalie |e investigator |4 oth | |
| 700 | 1 | |a Basak, Sambita |e investigator |4 oth | |
| 700 | 1 | |a Bishop, Linda |e investigator |4 oth | |
| 700 | 1 | |a Biswas, Chandrima |e investigator |4 oth | |
| 700 | 1 | |a Campbell, Deniesha |e investigator |4 oth | |
| 700 | 1 | |a Chados, Nikolaos |e investigator |4 oth | |
| 700 | 1 | |a Davies, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Davison, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Dudgeon, Lucy |e investigator |4 oth | |
| 700 | 1 | |a Ferry, Orla |e investigator |4 oth | |
| 700 | 1 | |a Ficquet, Jo |e investigator |4 oth | |
| 700 | 1 | |a Girling, Jo |e investigator |4 oth | |
| 700 | 1 | |a Gowans, Sharon |e investigator |4 oth | |
| 700 | 1 | |a Hewitt, Lesley |e investigator |4 oth | |
| 700 | 1 | |a Hinshaw, Kim |e investigator |4 oth | |
| 700 | 1 | |a Holt, Siobhan |e investigator |4 oth | |
| 700 | 1 | |a Jack, Elaine |e investigator |4 oth | |
| 700 | 1 | |a Jennings, Jacqui |e investigator |4 oth | |
| 700 | 1 | |a Maher, Martin |e investigator |4 oth | |
| 700 | 1 | |a McBean, Mel |e investigator |4 oth | |
| 700 | 1 | |a McDonnell, Sian |e investigator |4 oth | |
| 700 | 1 | |a Mehta, Anku |e investigator |4 oth | |
| 700 | 1 | |a Morris, Katie |e investigator |4 oth | |
| 700 | 1 | |a O'Brien, Clare |e investigator |4 oth | |
| 700 | 1 | |a Obiozo, Chinwe |e investigator |4 oth | |
| 700 | 1 | |a Peers, Beth |e investigator |4 oth | |
| 700 | 1 | |a Pickering, Francis |e investigator |4 oth | |
| 700 | 1 | |a Regan, Maeve |e investigator |4 oth | |
| 700 | 1 | |a Rich, Mel |e investigator |4 oth | |
| 700 | 1 | |a Roughley, Lindsay |e investigator |4 oth | |
| 700 | 1 | |a Ryan, Grace |e investigator |4 oth | |
| 700 | 1 | |a Sharp, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Smart, Brittany |e investigator |4 oth | |
| 700 | 1 | |a Smith, Annabel |e investigator |4 oth | |
| 700 | 1 | |a Stirrat, Laura |e investigator |4 oth | |
| 700 | 1 | |a Thompson, Hilary |e investigator |4 oth | |
| 700 | 1 | |a Trepte, Lauren |e investigator |4 oth | |
| 700 | 1 | |a Verghese, Lynda |e investigator |4 oth | |
| 700 | 1 | |a Willson, Seren |e investigator |4 oth | |
| 700 | 1 | |a Yulia, Angela |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 403(2024), 10427 vom: 17. Feb., Seite 619-631 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:403 |g year:2024 |g number:10427 |g day:17 |g month:02 |g pages:619-631 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0140-6736(23)02357-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 403 |j 2024 |e 10427 |b 17 |c 02 |h 619-631 | ||